We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed at $44.54 in the latest trading session, marking a +2.18% move from the prior day. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq decreased by 0.16%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.09% lagged the Medical sector's gain of 3.55% and the S&P 500's gain of 1.16%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on October 30, 2025. The company's upcoming EPS is projected at $1.55, signifying a 13.89% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.82 billion, down 0.65% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.42 per share and a revenue of $47.34 billion, signifying shifts of +458.26% and -1.98%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.55% lower. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 6.79. This denotes a discount relative to the industry average Forward P/E of 20.39.
It is also worth noting that BMY currently has a PEG ratio of 2.26. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.69.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed at $44.54 in the latest trading session, marking a +2.18% move from the prior day. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq decreased by 0.16%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.09% lagged the Medical sector's gain of 3.55% and the S&P 500's gain of 1.16%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on October 30, 2025. The company's upcoming EPS is projected at $1.55, signifying a 13.89% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.82 billion, down 0.65% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.42 per share and a revenue of $47.34 billion, signifying shifts of +458.26% and -1.98%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.55% lower. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 6.79. This denotes a discount relative to the industry average Forward P/E of 20.39.
It is also worth noting that BMY currently has a PEG ratio of 2.26. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.69.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.